Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS)

D.O. Arnar, G.H. Mairesse, G. Boriani, H. Calkins, A. Chin, A. Coats, J.-C. Deharo, J.H. Svendsen, H. Heidbüchel, R. Isa, J.M. Kalman, D.A. Lane, R. Louw, G.Y.H. Lip, P. Maury, T. Potpara, F. Sacher, P. Sanders, N. Varma, L. Fauchier

References      

  1. Raviele A, Giada F, Bergfeldt L, Blanc JJ, Blomstrom-Lundqvist C, Mont L et al. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. Europace 2011;13:920–34.
  2. Siontis KC, Gersh BJ, Killian JM, Noseworthy PA, McCabe P, Weston SA et al. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications. Heart Rhythm 2016;13:1418–24.
  3. Boriani  G,  Valzania  C,  Biffi  M,  Diemberger  I,  Ziacchi  M,  Martignani  C. Asymptomatic lone atrial fibrillation—how can we detect the arrhythmia? Curr Pharm Des 2015;21:659–66.
  4. Boriani G, Pettorelli D. Atrial fibrillation burden and atrial fibrillation type: clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vasc Pharmacol 2016;83:26–35.
  5. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J et al. Screening  for  atrial  fibrillation:  a  report  of  the  AF-SCREEN  International Collaboration. Circulation 2017;135:1851–67.
  6. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm  Society (HRS), Asia Pacific  Heart  Rhythm  Society  (APHRS),  and  Sociedad  Latinoamericana  de Estimulacion  Cardiaca  y  Electrofisiologia  (SOLAECE).  Europace  2017;19:1589–623.
  7. Priori SG, Blomstro¨ m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace 2015;17: 1601–87.
  8. Strickberger SA, Ip J, Saksena S, Curry K, Bahnson TD, Ziegler PD. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm 2005;2:125–31.
  9. Weber BE, Kapoor WN. Evaluation and outcomes of patients with palpitations. Am J Med 1996;100:138–48.
  10. Streur M, Ratcliffe SJ, Ball J, Stewart S, Riegel B. Symptom clusters in adults with chronic atrial fibrillation. J Cardiovasc Nurs 2017;32:296–303.
  11. Wieling W, Thijs  RD, van Dijk  N, Wilde  AA,  Benditt  DG, van Dijk  JG. Symptoms and signs of syncope: a review of the link between physiology and clinical clues. Brain 2009;132:2630–42.
  12. Malliani A, Recordati G, Schwartz PJ. Nervous activity of afferent cardiac sympathetic fibres with atrial and ventricular endings. J Physiol 1973;229:457–69.
  13. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res 2014;114:1004–21.
  14. Shivkumar K, Ajijola OA, Anand I, Armour JA, Chen P-S, Esler M et al. Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. J Physiol (Lond) 2016;594:3911–54.
  15. Schwartz PJ. Cardiac sympathetic denervation to prevent life-threatening arrhythmias. Nat Rev Cardiol 2014;11:346.
  16. Barsky AJ. Palpitations, arrhythmias, and awareness of cardiac activity. Ann Intern Med 2001;134:832–7.
  17. Peacock J, Whang W. Psychological distress and arrhythmia: risk prediction and potential modifiers. Prog Cardiovasc Dis 2013;55:582–9.
  18. Varounis C, Dagres N, Maounis T, Panagiotakos D, Cokkinos DV. Atrial premature complexes and heart rate have prognostic significance in 1-month atrial fibrillation recurrence after electrical cardioversion. Europace 2007;9:633–7.
  19. Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 2010;121:1904–11.
  20. Suzuki S, Sagara K, Otsuka T, Kano H, Matsuno S, Takai H et al. Usefulness of frequent supraventricular extrasystoles and a high CHADS2  score to predict first-time appearance of atrial fibrillation. Am J Cardiol 2013;111:1602–7.
  21. Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK et al. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med 2013;159:721–8.
  22. Larsen BS, Kumarathurai P, Falkenberg J, Nielsen OW, Sajadieh A. Excessive atrial ectopy and short atrial runs increase the risk of stroke beyond incident atrial fibrillation. J Am Coll Cardiol 2015;66:232–41.
  23. Marcus GM, Dewland TA. Premature atrial contractions: a wolf in sheep’s clothing? J Am Coll Cardiol 2015;66:242–4.
  24. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterisation, and clinical implication. Europace 2016;18:1455–90.
  25. Gudbjartsson DF, Holm H, Sulem P, Masson G, Oddsson A, Magnusson OT et al. A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. Eur Heart J 2017;38:27–34.
  26. Holm H, Gudbjartsson DF, Sulem P, Masson G, Helgadottir HT, Zanon C et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet 2011;43:316–20.
  27. Nattel S. Close connections between contraction and rhythm: a new genetic cause of atrial fibrillation/cardiomyopathy and what it can teach us. Eur Heart J 2017;38:35–7.
  28. Ahlberg G, Refsgaard L, Lundegaard PR, Andreasen L, Ranthe MF, Linscheid N et al. Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation. Nat Commun 2018;9:4316.
  29. Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke 2015;46:936–41.
  30. Davidoff R, Schamroth CL, Myburgh DP. The Wolff-Parkinson-White pattern in health aircrew. Aviat Space Environ Med 1981;52:554–8.
  31. Hiss  RG,  Lamb  LE.  Electrocardiographic  findings  in  122,043  individuals. Circulation 1962;25:947–61.
  32. Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard DJ et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993;87:866–73.
  33. Flensted-Jensen E. Wolff-Parkinson-White syndrome. A long-term follow-up of 47 cases. Acta Med Scand 1969;186:65–74.
  34. Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation 1990;82:1718–23.
  35. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al. ACC/AHA/ESC guidelines for the management of patients with supra-ventricular arrhythmias—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003;108:1871–909.
  36. Santinelli V, Radinovic A, Manguso F, Vicedomini G, Gulletta S, Paglino G et al. The natural history of asymptomatic ventricular pre-excitation a long-term prospective follow-up study of 184 asymptomatic children. J Am Coll Cardiol 2009; 53:275–80.
  37. Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979;301:1080–5.
  38. Kubuvs P, V´ıt P, Gebauer RA, Materna O, Janouvsek J. Electrophysiologic profile and results of invasive risk stratification in asymptomatic children and adolescents with the Wolff-Parkinson-White electrocardiographic pattern. Circ Arrhythm Electrophysiol 2014;7:218–23.
  39. Montoya PT, Brugada P, Smeets J, Talajic M, Della Bella P, Lezaun R et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991;12:144–50.
  40. Pappone C, Vicedomini G, Manguso F, Baldi M, Pappone A, Petretta A et al. Risk of malignant arrhythmias in initially symptomatic patients with Wolff-Parkinson-White syndrome: results of a prospective long-term electrophysiological follow-up study. Circulation 2012;125:661–8.
  41. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003;349:1803–11.
  42. Pappone C, Manguso F, Santinelli R, Vicedomini G, Sala S, Paglino G et al. Radiofrequency ablation in children with asymptomatic Wolff-Parkinson-White syndrome. N Engl J Med 2004;351:1197–205.
  43. Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD et al. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis. Circulation 2012;125:2308–15.
  44. Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation 2014;130:811–9.
  45. Al-Khatib SM, Arshad A, Balk EM, Das SR, Hsu JC, Joglar JA et al. Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: a systematic review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016;67:1624–38.
  46. Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana  de  Estimulacion  Cardiaca  y  Electrofisiologia  (SOLAECE). Europace 2017;19:465–511.
  47. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–78.
  48. Freedman  B,  Boriani  G,  Glotzer  TV,  Healey  JS,  Kirchhof  P,  Potpara  TS. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017;14:701–14.
  49. Gorenek BC, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV et al. Device-detected subclinical atrial tachyarrhythmias:  definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2017;19:1556–78.
  50. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840–4.
  51. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236–41.
  52. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99:3028–35.
  53. Flaker  GC,  Belew  K,  Beckman  K,  Vidaillet  H,  Kron  J,  Safford  R  et  al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:657–63.
  54. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110:213–22.
  55. Potpara TS, Polovina MM, Marinkovic JM, Lip GY. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 2013;168:4744–9.
  56. Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC, Investigators R. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm 2014;11:939–45.
  57. Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ et al. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 2015;8:393–402.
  58. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF pilot general registry. Am J Med 2015;128:509–18.e2.
  59. Esato M, Chun YH, An Y, Ogawa H, Wada H, Hasegawa K et al. Clinical impact of asymptomatic presentation status in patients with paroxysmal and sustained atrial fibrillation: the Fushimi AF registry. Chest 2017;152:1266–75.
  60. Tsang T, Barnes M, Pellikka P, Gin K, Miyasaka Y, Seward J et al. Silent atrial fibrillation in Olmsted County: a community-based study. Can J Cardiol 2011;27: S122.
  61. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005;112:307–13.
  62. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013;173:149–56.
  63. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm  Society  (APHRS),  and  Sociedad  Latinoamericana  de  Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2015;17:1747–69.
  64. Paquette M, Roy D, Talajic M, Newman D, Couturier A, Yang C et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol 2000;86:764–8.
  65. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. Thromb Haemost 2014; 112:276–86.
  66. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost 2017;117:1230–9.
  67. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet (Lond, Engl) 2016;388:806–17.
  68. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–76.
  69. Ruiz-Ortiz M, Bertomeu V, Cequier A, Marin F, Anguita M. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015;114:695–701.
  70. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017;14:627–8.
  71. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67.
  72. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (Lond, Engl) 2014;383:955–62.
  73. Potpara TS. Comparing non-vitamin K antagonist oral anticoagulants (NOACs) to different Coumadins: the Win-Win scenarios. Thromb Haemost 2018;118: 803–5.
  74. Freedman B, Martinez C, Katholing A, Rietbrock S. Residual risk of stroke and death in anticoagulant-treated patients with atrial fibrillation. JAMA Cardiol 2016; 1:366–8.
  75. Lip GYH, Lane DA, Potpara TS. Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Eur Heart J 2018;39:1404–6.
  76. Engdahl J, Holmen A, Rosenqvist M, Stromberg U. A prospective 5-year follow-up after population-based systematic screening for atrial fibrillation. Europace 2018;20:f306–11.
  77. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2017;20:e1–e160.
  78. Verma A, Ha ACT, Kirchhof P, Hindricks G, Healey JS, Hill MD et al. The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. Am Heart J 2018;197:124–32.
  79. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281–7a.
  80. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35:183–7.
  81. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy. J Am Coll Cardiol 2007;50:2156–61.
  82. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:2464–71.
  83. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J 2015;36:288–96.
  84. Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A et al. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol 2017;10.pii:e004267.
  85. Flaker G, Ezekowitz M, Yusuf S, Wallentin L, Noack H, Brueckmann M et al. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal,  persistent,  and  permanent  atrial  fibrillation:  results  from  the  RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J Am Coll Cardiol 2012;59:854–5.
  86. Senoo K, Lip GY, Lane DA, Buller HR, Kotecha D. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS Trial. Stroke 2015;46:2523–8.
  87. Lip GY, Frison L, Grind M, Investigators S. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008;264:50–61.
  88. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY et al. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol 2013;167:2682–7.
  89. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al. ‘Real-world’ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace 2016; 18:648–57.
  90. Inoue  H,  Atarashi  H,  Okumura  K,  Yamashita  T,  Kumagai  N,  Origasa  H. Thromboembolic events in paroxysmal vs. permanent non-valvular atrial fibrillation. Circ J 2014;78:2388–93.
  91. Takabayashi K, Hamatani Y, Yamashita Y, Takagi D, Unoki T, Ishii M et al. Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation: the Fushimi Atrial Fibrillation Registry. Stroke 2015;46:3354–61.
  92. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J 2016; 37:1591–602.
  93. Martin CA, Lambiase PD. Pathophysiology, diagnosis and treatment of tachycardiomyopathy. Heart (Br Cardiac Soc) 2017;103:1543–52.
  94. Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM, Ostojic MC et al. Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study. Int J Cardiol 2012;161:39–44.
  95. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O’Neill J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol  2012;5:632–9.
  96. Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA et al. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC Heart Fail 2017;5:44–52.
  97. Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016;18:12–36.
  98. Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484–92.
  99. Chen LY, Agarwal SK, Norby FL, Gottesman RF, Loehr LR, Soliman EZ et al. Persistent but not paroxysmal atrial fibrillation is independently associated with lower cognitive function: ARIC study. J Am Coll Cardiol 2016;67:1379–80.
  100. Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. Europace 2018;20:1399–421.
  101. Parkash R, Wells GA, Sapp JL, Healey JS, Tardif JC, Greiss I et al. Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]). Circulation 2017;135: 1788–98.
  102. Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Raisakis K et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol 2013;112:684–7.
  103. Chen LY, Bigger JT, Hickey KT, Chen H, Lopez-Jimenez C, Banerji MA et al. Effect of intensive blood pressure lowering on incident atrial fibrillation and P-wave indices in the ACCORD blood pressure trial. journal 2016;29:1276–82.
  104. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013;310:2050–60.
  105. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: a Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol 5;65: 2159–69.
  106. Bunch TJ, May HT, Bair TL, Crandall BG, Cutler MJ, Jacobs V et al. Long-term influence of body mass index on cardiovascular events after atrial fibrillation ablation. J Interv Card Electrophysiol 2016;46:259–65.
  107. Alonso A, Bahnson JL, Gaussoin SA, Bertoni AG, Johnson KC, Lewis CE et al. Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: the Look AHEAD randomized trial. Am Heart J 15;170: 770–7e5.
  108. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565–71.
  109. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: the CARDIO-FIT Study. J Am Coll Cardiol 2015;66:985–96.
  110. Qureshi WT, Alirhayim Z, Blaha MJ, Juraschek SP, Keteyian SJ, Brawner CA et al. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry Ford Exercise Testing (FIT) project. Circulation 2015;131:1827–34.
  111. Osbak PS, Mourier M, Kjaer A, Henriksen JH, Kofoed KF, Jensen GB. A randomized study of the effects of exercise training on patients with atrial fibrillation. Am Heart J 2011;162:1080–7.
  112. Malmo V, Nes BM, Amundsen BH, Tjonna AE, Stoylen A, Rossvoll O et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation 2016;133:466–73.
  113. Lampert R, Jamner L, Burg M, Dziura J, Brandt C, Liu H et al. Triggering of symptomatic atrial fibrillation by negative emotion. J Am Coll Cardiol 2014;64:1533–4.
  114. Lakkireddy D, Atkins D, Pillarisetti J, Ryschon K, Bommana S, Drisko J et al. Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study. J Am Coll Cardiol 2013; 61:1177–82.
  115. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:1501–8.
  116. Larsson SC, Drca N, Jensen-Urstad M, Wolk A. Combined impact of healthy lifestyle factors on risk of atrial fibrillation: prospective study in men and women. Int J Cardiol 2016;203:46–9.
  117. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol 2014; 64:2222–31.
  118. Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation 2018;137:e623–44.
  119. Karasoy D, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt M et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J 2015;36:307–14a.
  120. Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J 2016;37:2478–87.
  121. Saliba W, Schliamser JE, Lavi I, Barnett-Griness O, Gronich N, Rennert G. Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: a propensity score-matched analysis. Heart Rhythm 2017;14:635–42.
  122. Chang CH, Lin JW, Chiu FC, Caffrey JL, Wu LC, Lai MS. Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality: a nationwide cohort study and propensity score analysis. Circ Arrhythm Electrophysiol 2014;7:76–82.
  123. Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a propensity-matched analysis. Circ Cardiovasc Qual Outcomes  2012;5:171–81.
  124. Tran VN, Tessitore E, Gentil-Baron P, Jannot AS, Sunthorn H, Burri H et al. Thromboembolic events 7-11 years after catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 2015;38:499–506.
  125. Hussein AA, Saliba WI, Martin DO, Bhargava M, Sherman M, Magnelli-Reyes C et al. Natural history and long-term outcomes of ablated atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:271–8.
  126. Gaita F, Sardi D, Battaglia A, Gallo C, Toso E, Michielon A et al. Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation. Europace 2014;16:980–6.
  127. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes. J Interv Card Electrophysiol 2013;38:147–53.
  128. Guiot A, Jongnarangsin K, Chugh A, Suwanagool A, Latchamsetty R, Myles JD et al. Anticoagulant therapy and risk of cerebrovascular events after catheter ablation of atrial fibrillation in the elderly. J Cardiovasc Electrophysiol 2012;23: 36–43.
  129. Yagishita A, Takahashi Y, Takahashi A, Fujii A, Kusa S, Fujino T et al. Incidence of late thromboembolic events after catheter ablation of atrial fibrillation. Circ J 2011;75:2343–9.
  130. Saad EB, d’Avila A, Costa IP, Aryana A, Slater C, Costa RE et al. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score <_3: a long-term outcome study. Circ Arrhythm Electrophysiol 2011;4:615–21.
  131. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735–43.
  132. Oral H, Chugh A, O¨ Zaydın M, Good E, Fortino J, Sankaran S et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006;114:759–65.
  133. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS et al. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 2009;20:988–93.
  134. Potpara TS, Lip GY. Postapproval observational studies of non-vitamin K antagonist oral anticoagulants in atrial fibrillation. JAMA 2017;317:1115–6.
  135. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–27.
  136. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Moretz K et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: study rationale and design. Am Heart J 2018;199:192–9.
  137. Kalman JM, Sanders P, Rosso R, Calkins H. Should we perform catheter ablation for asymptomatic atrial fibrillation? Circulation 2017;136:490–9.
  138. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 2010;55: 2308–16.
  139. Wu L, Lu Y, Zheng L, Qiao YU, Chen G, Ding L et al. Comparison of radiofrequency catheter ablation between asymptomatic and symptomatic persistent atrial fibrillation: a propensity score matched analysis. J Cardiovasc Electrophysiol 2016;27:531–5.
  140. Mohanty S, Santangeli P, Mohanty P, Di Biase L, Holcomb S, Trivedi C et al. Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life, exercise performance, arrhythmia perception, and arrhythmia-free survival. J Cardiovasc Electrophysiol 2014;25:1057–64.
  141. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366: 120–9.
  142. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241–6.
  143. Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J 2018;39:1407–15.
  144. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol  2009;2:474–80.
  145. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–70.
  146. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094–9.
  147. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J 2015;36:1660–8.
  148. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J 2017;189:137–45.
  149. Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J 2017;190:12–8.
  150. von Rotz M, Aeschbacher S, Bossard M, Schoen T, Blum S, Schneider S et al. Risk factors for premature ventricular contractions in young and healthy adults. Heart 2017;103:702–7.
  151. Lee V, Perera D, Lambiase P. Prognostic significance of exercise-induced premature ventricular complexes: a systematic review and meta-analysis of observational studies. Heart Asia 2017;9:14–24.
  152. Lin CY, Chang SL, Chung FP, Chen YY, Lin YJ, Lo LW et al. Long-term outcome of non-sustained ventricular tachycardia in structurally normal hearts. PLoS One 2016;11:e0160181.
  153. Biffi A, Pelliccia A, Verdile L, Fernando F, Spataro A, Caselli S et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol 2002;40:446–52.
  154. Ataklte F, Erqou S, Laukkanen J, Kaptoge S. Meta-analysis of ventricular prem ture complexes and their relation to cardiac mortality in general populations. Am J Cardiol 2013;112:1263–70.
  155. Hutchinson MD, Garcia FC. An organized approach to the localization, mapping, and ablation of outflow tract ventricular arrhythmias. J Cardiovasc Electrophysiol  2013;24:1189–97.
  156. Novak J, Zorzi A, Castelletti S, Pantasis A, Rigato I, Corrado D et al. Electrocardiographic differentiation of idiopathic right ventricular outflow tract ectopy from early arrhythmogenic right ventricular cardiomyopathy. Europace 2017;19:622–8.
  157. Saberniak J, Leren IS, Haland TF, Beitnes JO, Hopp E, Borgquist R et al. Comparison of patients with early-phase arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract ventricular tachycardia. Eur Heart J Cardiovasc Imaging 2017;18:62–9.
  158. Luebbert J, Auberson D, Marchlinski F. Premature ventricular complexes in apparently normal hearts. Card Electrophysiol Clin 2016;8:503–14.
  159. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al. AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2017;138: e272–391.
  160. Latchamsetty R, Bogun F. Premature ventricular complexes and premature ventricular complex induced cardiomyopathy. Curr Probl Cardiol 2015;40:379–422.
  161. Yokokawa M, Kim HM, Good E, Chugh A, Pelosi F Jr, Alguire C et al. Relation of symptoms and symptom duration to premature ventricular complex-induced cardiomyopathy. Heart Rhythm 2012;9:92–5.
  162. Olgun H, Yokokawa M, Baman T, Kim HM, Armstrong W, Good E et al. The role of interpolation in PVC-induced cardiomyopathy. Heart Rhythm 2011;8: 1046–9.
  163. Carballeira Pol L, Deyell MW, Frankel DS, Benhayon D, Squara F, Chik W et al. Ventricular premature depolarization QRS duration as a new marker of risk for the development of ventricular premature depolarization-induced cardiomyopathy. Heart Rhythm 2014;11:299–306.
  164. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010;7:865–9.
  165. Hasdemir C, Ulucan C, Yavuzgil O, Yuksel A, Kartal Y, Simsek E et al. Tachycardia-induced cardiomyopathy in patients with  idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol 2011;22:663–8.
  166. Del Carpio Munoz F, Syed FF, Noheria A, Cha YM, Friedman PA, Hammill SC et al. Characteristics of premature ventricular complexes as correlates of reduced left ventricular systolic function: study of the burden, duration, coupling interval, morphology and site of origin of PVCs. J Cardiovasc Electrophysiol 2011; 22:791–8.
  167. 167.               Ban   JE,   Park   HC,   Park   JS,   Nagamoto   Y,   Choi   JI,   Lim   HE   et   al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace 2013;15:735–41.
  168. Sadron Blaye-Felice M, Hamon D, Sacher F, Pascale P, Rollin A, Duparc A et al. Premature ventricular contraction-induced cardiomyopathy: related clinical and electrophysiologic parameters. Heart Rhythm 2016;13:103–10.
  169. Lie OH, Saberniak J, Dejgaard LA, Stokke MK, Hegbom F, Anfinsen OG et al. Lower than expected burden of premature ventricular contractions impairs myocardial function. ESC Heart Fail 2017;4:585–94.
  170. Park KM, Im SI, Park SJ, Kim JS, On YK. Risk factor algorithm used to predict frequent premature ventricular contraction-induced cardiomyopathy. Int J Cardiol 2017;233:37–42.
  171. Loring Z, Hanna P, Pellegrini CN. Longer ambulatory ECG monitoring increases identification of clinically significant ectopy. Pacing Clin Electrophysiol 2016;39: 592–7.
  172. Niwano S, Wakisaka Y, Niwano H, Fukaya H, Kurokawa S, Kiryu M et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart 2009;95:1230–7.
  173. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS et al. Ventricular ectopy as a predictor of heart failure and death. J Am Coll Cardiol 2015;66:101–9.
  174. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–8.
  175. Folarin VA, Fitzsimmons PJ, Kruyer WB. Holter monitor findings in asymptomatic male military aviators without structural heart disease. Aviat Space Environ Med 2001;72:836–8.
  176. Marine JE, Shetty V, Chow GV, Wright JG, Gerstenblith G, Najjar SS et al. Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging). J Am Coll Cardiol 2013;62:595–600.
  177. Gheno G, Mazzei G. Prognostic value of Holter monitoring in asymptomatic el derly subjects with sinus rhythm. J Electrocardiol 1996;29:39–44.
  178. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746–837.
  179. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J et al. J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. J Arrhythm 2016;32:315–39.
  180. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm 2004;1:276–83.
  181. Denis A, Sacher F, Derval N, Lim HS, Cochet H, Shah AJ et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 2014;7:590–7.
  182. Good E, Desjardins B, Jongnarangsin K, Oral H, Chugh A, Ebinger M et al. Ventricular arrhythmias originating from a papillary muscle in patients without prior infarction: a comparison with fascicular arrhythmias. Heart Rhythm 2008;5: 1530–7.
  183. Jastrzebski M, Bacior B. Repetitive monomorphic ventricular tachycardia originating from the inferior tricuspid annulus. Cardiol J 2008;15:277–80.
  184. Yamauchi Y, Aonuma K, Takahashi A, Sekiguchi Y, Hachiya H, Yokoyama Y et al. Electrocardiographic characteristics of repetitive monomorphic right ventricular tachycardia originating near the His-bundle. J Cardiovasc Electrophysiol 2005;16:1041–8.
  185. Arias MA, Puchol A, Pachon M, Akerstrom F, Rodriguez-Padial L. Nonsustained repetitive upper septal idiopathic fascicular left ventricular tachycardia. Rev Esp Cardiol (Engl Ed) 2016;69:221–4.
  186. Morgera T, Hrovatin E, Mazzone C, Humar F, De Biasio M, Salvi A. Clinical spectrum of fascicular tachycardia. J Cardiovasc Med (Hagerstown, MD) 2013;14: 791–8.
  187. Lin D, Hsia HH, Gerstenfeld EP, Dixit S, Callans DJ, Nayak H et al. Idiopathic fascicular left ventricular tachycardia: linear ablation lesion strategy for noninducible or nonsustained tachycardia. Heart Rhythm 2005;2:934–9.
  188. Toivonen L, Nieminen M. Persistent ventricular tachycardia resulting in left ventricular dilatation treated with verapamil. Int J Cardiol 1986;13:361–5.
  189. Kennedy HL, Whitlock JA, Sprague MK, Kennedy LJ, Buckingham TA, Goldberg RJ. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N Engl J Med 1985;312:193–7.
  190. Kane A, Defaye P, Jacon P, Mbaye A, Machecourt J. Malignant fascicular ventricular tachycardia degenerating into ventricular fibrillation in a patient with early repolarization syndrome. Ann Cardiol Angeiol 2012;61:292–5.
  191. Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996;19:95–106.
  192. Haissaguerre M, Shah DC, Jais P, Shoda M, Kautzner J, Arentz T et al. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet (Lond, Engl) 2002;359:677–8.
  193. Viskin S, Rosso R, Rogowski O, Belhassen B. The “short-coupled” variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol 2005;16:912–6.
  194. Noda T, Shimizu W, Taguchi A, Aiba T, Satomi K, Suyama K et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular out-flow tract. J Am Coll Cardiol 2005;46:1288–94.
  195. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F et al. Radiofrequency ablation as primary management of well-tolerated sustained monomorphic ventricular tachycardia in patients with structural heart disease and left ventricular ejection fraction over 30%. Eur Heart J 2014;35:1479–85.
  196. Corrado D, Wichter T, Link MS, Hauer RN, Marchlinski FE, Anastasakis A et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an International Task Force Consensus Statement. Circulation 2015;132:441–53.
  197. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481–8.
  198. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427–36.
  199. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933–40.
  200. Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer GS, Prystowsky EN et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 2000;342:1937–45.
  201. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.
  202. Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T et al. EHRA/HRS/APHRS  expert  consensus  on  ventricular  arrhythmias.  Europace 2014;16:1257–83.
  203. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
  204. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol 2003;41:1707–12.
  205. Dejgaard LA, Skjølsvik ET, Lie ØH, Ribe M, Stokke MK, Hegbom F et al. The mitral annulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600–9.
  206. Sriram CS, Syed FF, Ferguson ME, Johnson JN, Enriquez-Sarano M, Cetta F et al. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. J Am Coll Cardiol 2013;62:222–30.
  207. Basso C, Perazzolo Marra M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A et al. Arrhythmic mitral valve prolapse and sudden cardiac death. Circulation 2015; 132:556–66.
  208. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.
  209. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy under-going implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 2011;58:1485–96.
  210. Gatzoulis KA, Tsiachris D, Arsenos P, Archontakis S, Dilaveris P, Vouliotis A et al. Prognostic value of programmed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int J Cardiol 2014;176:1449–51.
  211. Olgin  JE, Pletcher MJ,  Vittinghoff E,  Wranicz J, Malik R, Morin DP  et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med 2018;379:1205–15.
  212. Nakahara S, Chien C, Gelow J, Dalouk K, Henrikson CA, Mudd  J et al. Ventricular arrhythmias after left ventricular assist device. Circ Arrhythm Electrophysiol  2013;6:648–54.
  213. Sacher F, Reichlin T, Zado ES, Field ME, Viles-Gonzalez JF, Peichl P et al. Characteristics of ventricular tachycardia ablation in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol 2015;8:592–7.
  214. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace  2013;15:1389–406.
  215. Laurent G, Saal S, Amarouch MY, Beziau DM, Marsman RF, Faivre L et al. Multifocal ectopic Purkinje-related premature contractions: a new SCN5A-related cardiac channelopathy. J Am Coll Cardiol 2012;60:144–56.
  216. Delannoy E, Sacher F, Maury P, Mabo P, Mansourati J, Magnin I et al. Cardiac characteristics and long-term outcome in Andersen–Tawil syndrome patients related to KCNJ2 mutation. Europace 2013;15:1805–11.
  217. Verdile L, Maron BJ, Pelliccia A, Spataro A, Santini M, Biffi A. Clinical significance of exercise-induced ventricular tachyarrhythmias in trained athletes without cardiovascular abnormalities. Heart Rhythm 2015;12:78–85.
  218. Venlet J, Piers SR, Jongbloed JD, Androulakis AF, Naruse Y, den Uijl DW et al. Isolated subepicardial right ventricular outflow tract scar in athletes with ventricular tachycardia. J Am Coll Cardiol2017;69:497–507.
  219. Li JM, Nguyen C, Joglar JA, Hamdan MH, Page RL. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 2008;31:538–41.
  220. Bertels RA, Harteveld LM, Filippini LH, Clur SA, Blom NA. Left ventricular dysfunction is associated with frequent premature ventricular complexes and asymptomatic ventricular tachycardia in children. Europace 2017;19:617–21.
  221. Levin MD, Stephens P, Tanel RE, Vetter VL, Rhodes LA. Ventricular tachycardia in infants with structurally normal heart: a benign disorder. Cardiol Young 2010; 20:641–7.
  222. Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 2008; 117:363–70.
  223. Koyak Z, de Groot JR, Bouma BJ, Van Gelder IC, Budts W, Zwinderman AH et al. Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int J Cardiol 2013;167:1532–5.
  224. Wong MCG, Kalman JM, Pedagogos E, Toussaint N, Vohra JK, Sparks PB et al. Bradycardia and asystole is the predominant mechanism of sudden cardiac death in patients with chronic kidney disease. J Am Coll Cardiol 2015;65:1263–5.
  225. Sacher F, Jesel L, Borni-Duval C, De Precigout V, Lavainne F, Bourdenx JP et al. Cardiac rhythm disturbances in hemodialysis patients: early detection using an implantable loop recorder and correlation with biological and dialysis parameters. JACC Clin Electrophysiol 2018;4:397–408.
  226. Rudzinski T, Ciesielczyk M, Religa W, Bednarkiewicz Z, Krzeminska-Pakula M. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator. Europace 2007;9:278–80.
  227. Yanamandra U, Gupta S, Khadwal A, Malhotra P. Melphalan-induced cardiotoxicity: ventricular arrhythmias. BMJ Case Rep 2016;pii:bcr2016218652.
  228. Grimm W, Hoffmann J, Menz V, Schmidt C, Muller HH, Maisch B. Significance of accelerated idioventricular rhythm in idiopathic dilated cardiomyopathy. Am J Cardiol 2000;85:899–904, a10.
  229. MacLellan-Tobert SG, Porter CJ. Accelerated idioventricular rhythm: a benign arrhythmia in childhood. Pediatrics 1995;96:122–5.
  230. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol 2017;70:1949–61.
  231. Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol 2014;172:40–6.
  232. Nakatani BT, Minicucci MF, Okoshi K, Politi Okoshi M. Tachycardia-induced cardiomyopathy. BMJ Case Rep 2012;pii: bcr2012006587.
  233. Lishmanov A, Chockalingam P, Senthilkumar A, Chockalingam A. Tachycardia-induced cardiomyopathy: evaluation and therapeutic options. Congest Heart Fail 2010;16:122–6.
  234. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004;110:247–52.
  235. Donghua Z, Jian P, Zhongbo X, Feifei Z, Xinhui P, Hao Y et al. Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia. J Interv Card Electrophysiol 2013;36:27–32.
  236. Kang KT, Potts JE, Radbill AE, La Page MJ, Papagiannis J, Garnreiter JM et al. Permanent junctional reciprocating tachycardia in children: a multicenter experience. Heart Rhythm 2014;11:1426–32.
  237. Nia AM, Gassanov N, Dahlem KM, Caglayan E, Hellmich M, Erdmann E et al. Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clin Res Cardiol 2011;100: 887–96.
  238. Yokokawa M, Kim HM, Good E, Crawford T, Chugh A, Pelosi F Jr et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm 2012;9:1460–4.
  239. Ling LH, Kalman JM, Ellims AH, Iles LM, Medi C, Sherratt C et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol 2013;6:697–704.
  240. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.
  241. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet 2016;388:829–40.
  242. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013;61:1894–903.
  243. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133:1637–44.
  244. Prabhu S, Costello BT, Taylor AJ, Gutman SJ, Voskoboinik A, McLellan AJA et al. Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy of the CAMERA MRI trial. JACC Clin Electrophysiol 2018;4:999–1007.
  245. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol 2015;66:1714–28.
  246. Garcia B, Clementy N, Benhenda N, Pierre B, Babuty D, Olshansky B et al. Mortality after atrioventricular nodal radiofrequency catheter ablation with permanent ventricular pacing in atrial fibrillation: outcomes from a controlled non-randomized study. Circ Arrhythm Electrophysiol 2016;9.pii:e003993.
  247. Vijayaraman P, Chung MK, Dandamudi G, Upadhyay GA, Krishnan K, Crossley G et al. His bundle pacing. J Am Coll Cardiol 2018;72:927–47.
  248. Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB et al. Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations. Eur J Heart Fail 2017;20:1472–81.
  249. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol 2012;59:719–26.
  250. Krittayaphong R, Bhuripanyo K, Punlee K, Kangkagate C, Chaithiraphan S. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J 2002;144:e10.
  251. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77–82.
  252. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857–65.
  253. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005; 112:1092–7.
  254. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007;4:863–7.
  255. Taieb JM, Maury P, Shah D, Duparc A, Galinier M, Delay M et al. Reversal of dilated cardiomyopathy by the elimination of frequent left or right premature ventricular contractions. J Interv Card Electrophysiol 2007;20:9–13.
  256. Sekiguchi Y, Aonuma K, Yamauchi Y, Obayashi T, Niwa A, Hachiya H et al. Chronic hemodynamic effects after radiofrequency catheter ablation of frequent monomorphic ventricular premature beats. J Cardiovasc Electrophysiol 2005;16:1057–63.
  257. Hasdemir C, Kartal Y, Simsek E, Yavuzgil O, Aydin M, Can LH. Time course of recovery of left ventricular systolic dysfunction in patients with premature ventricular contraction-induced cardiomyopathy. Pacing Clin Electrophysiol 2013;36: 612–7.
  258. Goldberger JJ, Johnson NP, Gidea C. Significance of asymptomatic bradycardia for subsequent pacemaker implantation and mortality in patients >60 years of age. Am J Cardiol 2011;108:857–61.
  259. Molgaard H, Sorensen KE, Bjerregaard P. Minimal heart rates and longest pauses in healthy adult subjects on two occasions eight years apart. Eur Heart J 1989;10:758–64.
  260. Wajngarten M, Grupi C, Bellotti GM, Da Luz PL, Azul LG, Pileggi F. Frequency and significance of cardiac rhythm disturbances in healthy elderly individuals. J Electrocardiol 1990;23:171–6.
  261. Senturk T, Xu H, Puppala K, Krishnan B, Sakaguchi S, Chen LY et al. Cardiac pauses in competitive athletes: a systematic review examining the basis of current practice recommendations. Europace 2016;18:1873–9.
  262. Krahn AD, Klein GJ, Yee R, Skanes AC. Detection of asymptomatic arrhythmias in unexplained syncope. Am Heart J 2004;148:326–32.
  263. Moya A, Brignole M, Sutton R, Menozzi C, Garcia-Civera R, Wieling W et al. Reproducibility of electrocardiographic findings in patients with suspected reflex neurally-mediated syncope. Am J Cardiol 2008;102:1518–23.
  264. Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour Holter recordings. Am J Cardiol 1985; 55:1005–8.
  265. Becker HF, Koehler U, Stammnitz A, Peter JH. Heart block in patients with sleep apnoea. Thorax 1998;53 Suppl 3:S29–32.
  266. Coumbe AG, Naksuk N, Newell MC, Somasundaram PE, Benditt DG, Adabag S. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart (Br Cardiac Soc) 2013;99:334–8.
  267. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA et al. ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070–118.
  268. Kusumoto Fred M, Schoenfeld Mark H, Barrett C, Edgerton James R, Ellenbogen Kenneth A, Gold Michael R et al. ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. Circulation 2018;doi: 10.1161/CIR.0000000000000628.
  269. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest 2007;132:1259–64.
  270. Hamang A, Eide GE, Rokne B, Nordin K, Oyen N. General anxiety, depression, and physical health in relation to symptoms of heart-focused anxiety—a cross sectional study among patients living with the risk of serious arrhythmias and sudden cardiac death. Health Qual Life Outcomes 2011;9:100.
  271. McCabe PJ. Psychological distress in patients diagnosed with atrial fibrillation. The State of the Science. J Cardiovasc Nurs 2010;25:40–51.
  272. Patel D, Mc Conkey ND, Sohaney R, Mc Neil A, Jedrzejczyk A, Armaganijan L. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol 2013;2013:1.
  273. Shea JB. Quality of life issues in patients with implantable cardioverter defibrillators: driving, occupation, and recreation. AACN Clin Issues 2004;15:478–89.
  274. McCabe PJ. What patients want and need to know about atrial fibrillation. J Multidiscip Healthc 2011;4:413–9.
  275. Ooi SL, He HG, Dong Y, Wang W. Perceptions and experiences of patients living with implantable cardioverter defibrillators: a systematic review and meta-synthesis. Health Qual Life Outcomes 2016;14:160.
  276. Lane DA, Barker RV, Lip GY. Best practice for atrial fibrillation patient education. Curr Pharm Des 2015;21:533–43.
  277. Bjorkenheim A, Brandes A, Magnuson A, Chemnitz A, Edvardsson N, Poci D. Patient-reported outcomes in relation to continuously monitored rhythm before and during 2 years after atrial fibrillation ablation using a disease-specific and a generic instrument. J Am Heart Assoc 2018;7.pii:e008362.
  278. Lang S, Becker R, Wilke S, Hartmann M, Herzog W, Lowe B. Anxiety disorders in patients with implantable cardioverter defibrillators: frequency, course, predictors, and patients’ requests for treatment. Pacing Clin Electrophysiol 2014;37: 35–47.
  279. Magyar-Russell G, Thombs BD, Cai JX, Baveja T, Kuhl EA, Singh PP et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res 2011;71:223–31.
  280. Mastenbroek MH, Denollet J, Versteeg H, van den Broek KC, Theuns DA, Meine M et al. Trajectories of patient-reported health status in patients with an implantable cardioverter defibrillator. Am J Cardiol 2015;115:771–7.
  281. Pepine CJ. Effects of pharmacologic therapy on health-related quality of life in elderly patients with atrial fibrillation: a systematic review of randomized and nonrandomized trials. Clin Med Insights Cardiol 2013;7:1–20.
  282. Wood KA, Stewart AL, Drew BJ, Scheinman MM, Froelicher ES. Patient perception of symptoms and quality of life following ablation in patients with supraventricular tachycardia. Heart Lung 2010;39:12–20.
  283. Turakhia MP, Desai M, Hedlin H, Rajmane A, Talati N, Ferris T et  al. Rationale and design of a large-scale, appbased study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. Am Heart J 2019;207: 66–75.
[PDF] [Contents]